DB:6ML

Stock Analysis Report

Executive Summary

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products.

Rewards

Earnings are forecast to grow 54.24% per year

Risk Analysis

No risks detected for 6ML from our risk checks.


Snowflake Analysis

Exceptional growth potential with flawless balance sheet.

Share Price & News

How has Molecular Partners's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6ML has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

6ML

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-32.8%

6ML

-13.5%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 6ML underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: 6ML underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

6MLIndustryMarket
7 Day0%-0.7%-0.6%
30 Day0%-7.8%-16.6%
90 Day0.3%-21.1%-26.0%
1 Year-32.8%-32.8%-13.3%-13.5%-18.6%-20.9%
3 Year-43.7%-43.7%14.1%12.9%-19.0%-25.8%
5 Yearn/a-9.6%-11.9%-21.1%-31.8%

Price Volatility Vs. Market

How volatile is Molecular Partners's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Molecular Partners undervalued compared to its fair value and its price relative to the market?

4.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6ML's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6ML's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6ML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6ML is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6ML's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6ML is overvalued based on its PB Ratio (4.6x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Molecular Partners forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

54.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6ML is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 6ML is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6ML's is expected to become profitable in the next 3 years.

Revenue vs Market: 6ML's revenue (30.4% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: 6ML's revenue (30.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6ML's Return on Equity is forecast to be high in 3 years time (26.6%)


Next Steps

Past Performance

How has Molecular Partners performed over the past 5 years?

-45.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6ML is currently unprofitable.

Growing Profit Margin: 6ML is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6ML is unprofitable, and losses have increased over the past 5 years at a rate of -45% per year.

Accelerating Growth: Unable to compare 6ML's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6ML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: 6ML has a negative Return on Equity (-48.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Molecular Partners's financial position?


Financial Position Analysis

Short Term Liabilities: 6ML's short term assets (CHF129.5M) exceed its short term liabilities (CHF34.5M).

Long Term Liabilities: 6ML's short term assets (CHF129.5M) exceed its long term liabilities (CHF22.3M).


Debt to Equity History and Analysis

Debt Level: 6ML is debt free.

Reducing Debt: 6ML has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 6ML has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 6ML's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 6ML has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 6ML is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -11.8% per year.


Next Steps

Dividend

What is Molecular Partners's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6ML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6ML's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6ML's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6ML's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6ML's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Patrick Amstutz (44yo)

2.83s

Tenure

CHF909,000

Compensation

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting C ...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD918.08K) is about average for companies of similar size in the German market ($USD817.80K).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder2.83yrsCHF909.00k3.24% CHF10.8m
Michael Stumpp
Co-Founder15.67yrsno data3.51% CHF11.7m
Andreas Emmenegger
CFO & Member of Management Board12.42yrsno data1.1% CHF3.7m
Nicolas Leupin
Chief Medical Officer & Member of Management Boardno datano datano data
Hans Binz
Vice President of Technologyno datano datano data
Thomas Schneckenburger
Vice President of Financeno datano datano data
Julien Gander
General Counsel3.17yrsno datano data
Thomas Schwerzmann
Vice President of Human Resources0.42yrno datano data
Andreas Harstrick
Executive Officerno datano datano data
Alexander Zürcher
Senior Vice President of Development0.42yrno datano data

3.0yrs

Average Tenure

47yo

Average Age

Experienced Management: 6ML's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Patrick Amstutz
Co-Founder2.83yrsCHF909.00k3.24% CHF10.8m
Steven Holtzman
Non Executive Director5.67yrsCHF95.00k0.0099% CHF32.9k
Göran Ando
Vice-Chairman of the Board of Directors1.5yrsCHF98.00k0.0099% CHF32.9k
Petri Vainio
Non Executive Director10.67yrsCHF103.00k0.0099% CHF32.9k
William Lee
Non Executive Director12.67yrsCHF106.00k0.010% CHF33.1k
William A. Burns
Chairman of the Board1.42yrsCHF305.00kno data
Gwen Fyfe
Director2.33yrsCHF96.00kno data

2.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 6ML's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Molecular Partners AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Molecular Partners AG
  • Ticker: 6ML
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF360.544m
  • Listing Market Cap: CHF332.464m
  • Shares outstanding: 21.38m
  • Website: https://www.molecularpartners.com

Number of Employees


Location

  • Molecular Partners AG
  • Wagistrasse 14
  • Schlieren
  • Zurich
  • 8952
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOLNSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFNov 2014
0QXXLSE (London Stock Exchange)YesRegistered SharesGBCHFNov 2014
6MLDB (Deutsche Boerse AG)YesRegistered SharesDEEURNov 2014
MLLC.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDNov 2014

Biography

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema diseases, as well as on a partnered pipeline that includes novel approaches to the treatment of severe ocular diseases. The company also develops MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc.; Janssen Biotech, Inc.; and Amgen SA. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/25 22:29
End of Day Share Price2019/06/28 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.